Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics : a multicentre economic evaluation

Simple item page
dc.contributor.authorPooran, Anilen_ZA
dc.contributor.authorTheron, Granten_ZA
dc.contributor.authorZijenah, Lynnen_ZA
dc.contributor.authorChanda, Duncanen_ZA
dc.contributor.authorClowes, Petraen_ZA
dc.contributor.authorMwenge, Lawrenceen_ZA
dc.contributor.authorMutenherwa, Fariraien_ZA
dc.contributor.authorLecesse, Paulen_ZA
dc.contributor.authorMetcalfe, Johnen_ZA
dc.contributor.authorSohn, Hojoonen_ZA
dc.contributor.authorHoelscher, Michaelen_ZA
dc.contributor.authorPym, Alexen_ZA
dc.contributor.authorPeter, Jonnyen_ZA
dc.contributor.authorDowdy, Daviden_ZA
dc.contributor.authorDheda, Keertanen_ZA
dc.date.accessioned2021-10-11T14:02:16Z
dc.date.available2021-10-11T14:02:16Z
dc.date.issued2019-06-01
dc.descriptionCITATION: Pooran, A., et al. 2019. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics : a multicentre economic evaluation. The Lancet Global Health, 7(6):E798-E807. doi:10.1016/S2214-109X(19)30164-0
dc.descriptionThe original publication is available at https://www.thelancet.com/journals/langlo/home
dc.description.abstractBackground: Rapid on-site diagnosis facilitates tuberculosis control. Performing Xpert MTB/RIF (Xpert) at point of care is feasible, even when performed by minimally trained health-care workers, and when compared with point-of-care smear microscopy, reduces time to diagnosis and pretreatment loss to follow-up. However, whether Xpert is cost-effective at point of care remains unclear. Methods: We empirically collected cost (US$, 2014) and clinical outcome data from participants presenting to primary health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania) during the TB-NEAT trial. Costs were determined using an bottom-up ingredients approach. Effectiveness measures from the trial included number of cases diagnosed, initiated on treatment, and completing treatment. The primary outcome was the incremental cost-effectiveness of point-of-care Xpert relative to smear microscopy. The study was performed from the perspective of the health-care provider. Findings: Using data from 1502 patients, we calculated that the mean Xpert unit cost was lower when performed at a centralised laboratory (Lab Xpert) rather than at point of care ($23·00 [95% CI 22·12–23·88] vs $28·03 [26·19–29·87]). Per 1000 patients screened, and relative to smear microscopy, point-of-care Xpert cost an additional $35 529 (27 054–40 025) and was associated with an additional 24·3 treatment initiations ([–20·0 to 68·5]; $1464 per treatment), 63·4 same-day treatment initiations ([27·3–99·4]; $511 per same-day treatment), and 29·4 treatment completions ([–6·9 to 65·6]; $1211 per completion). Xpert costs were most sensitive to test volume, whereas incremental outcomes were most sensitive to the number of patients initiating and completing treatment. The probability of point-of-care Xpert being cost-effective was 90% at a willingness to pay of $3820 per treatment completion. Interpretation: In southern Africa, although point-of-care Xpert unit cost is higher than Lab Xpert, it is likely to offer good value for money relative to smear microscopy. With the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation strategies in tuberculosis endemic settings.en_ZA
dc.description.urihttps://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30164-0/fulltext
dc.description.versionPublisher’s version
dc.format.extent10 pagesen_ZA
dc.identifier.citationPooran, A., et al. 2019. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. The Lancet Global Health, 7(6):E798-E807. doi:10.1016/S2214-109X(19)30164-0
dc.identifier.issn2214-109X (online)
dc.identifier.otherdoi:10.1016/S2214-109X(19)30164-0
dc.identifier.urihttp://hdl.handle.net/10019.1/123205
dc.language.isoen_ZAen_ZA
dc.publisherElsevieren_ZA
dc.rights.holderAuthors retain rightsen_ZA
dc.subjectXpert MTB/RIFen_ZA
dc.subjectTuberculosis -- Diagnosisen_ZA
dc.subjectPrimary health care -- South Africaen_ZA
dc.subjectMedical microscopyen_ZA
dc.titlePoint of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics : a multicentre economic evaluationen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pooran_point_2019.pdf
Size:
576.1 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Desmond Tutu TB Centre)